Biotech grants in Denmark

Closed

Funds clinical and pre-clinical research that pins down the causes of, and builds better diagnostics and treatments for, medical conditions that are common but poorly understood, such as ME/CFS, autism, gynaecological diseases and low back pain.

Funds beyond-proof-of-concept innovations that make infectious-disease prevention, treatment or diagnostics cheaper, more accessible or better suited to sub-Saharan Africa.

Closed

Pays biomedical New Approach Methodology developers a fixed EUR 300,000 lump-sum grant to validate animal-free testing methods and prepare them for regulatory use.

Funds one project mining research cohorts and biobanks to find causal links between infections and non-communicable diseases, aimed at new vaccines, diagnostics and early treatments.

Closed

Funds research into how environmental exposures interact with genetic and lifestyle factors to cause cancer in children, adolescents and young adults.

Closed

Funds AI and digital-twin tools that speed up bio-based manufacturing — from biorefinery process control to predicting biosynthesis pathways.

Funds a full-scale flagship biorefinery that turns separately-collected urban bio-waste into higher-value bio-based products instead of compost or biomethane.

Closed

Funds the advancement of existing vaccine candidates against one named epidemic-prone virus, from lab testing through to a first human safety trial.

Funds research into new tools and conversion routes that turn low-value forest residues into bio-based chemicals, materials or products beyond bioenergy.

Open

Funds Danish companies preparing Horizon Europe and EDF proposals by supporting proposal development.

Open

Supports Alzheimer’s and dementia drug development from preclinical readiness to early clinical testing across diverse modalities.

Open

Funds new biomarkers for Alzheimer's and related dementias through PET ligands, MRI, spinal fluid, and brain activity measures.

Open

Supports dementia prevention research through precision risk reduction, combination treatment testing, and effectiveness comparisons.

Open

Funds a consortium to build a new EIT Label-certified micro-credentials programme teaching entrepreneurship and innovation to healthcare students.

Funds small, high-risk exploratory research into reconstructive transplantation and vascularized composite allotransplantation for wounded Service Members and Veterans.

Pays $10,000 for a genuinely new way to verify cleanliness in under 30 minutes.

Open

Funds four centres to work out how cancer actually spreads — each on one theme, through two or three interlocking basic research projects.

Open

Supports global cancer teams through CRUK to validate novel therapeutic concepts toward patient solutions.

Funds teams up to $800,000 to build cheap pathogen-sequencing workflows for poorer countries.

Open

Funds research teams building low-cost, simplified pathogen-sequencing workflows that bring the cost of sequencing a sample down to about US$1-10 for use in low- and middle-income countries.

Open

Funds one centre that trains researchers in formal drug development for substance use disorder and pays to test their best ideas.

Open

Funds high-risk clinical trials of new ways to see inside the living human inner ear. A trial is compulsory, and NIH stays in the room.

Open

Funds building the imaging that can finally show hair cells and membranes inside a living human ear. A clinical trial is optional.

Open

Funds researchers combining computational and experimental approaches to test repositioned drugs for Alzheimer's disease treatment through NIH R01 grants.